Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) EBIAT (2022 - 2025)

Core Laboratories' EBIAT history spans 4 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, EBIAT fell 37.11% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $29.8 million, down 7.62%, while the annual FY2025 figure was $30.4 million, 5.48% down from the prior year.
  • EBIAT reached $5.1 million in Q4 2025 per CLB's latest filing, down from $14.2 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $22.8 million in Q2 2023 to a low of -$154000.0 in Q1 2025.
  • Average EBIAT over 4 years is $8.1 million, with a median of $7.7 million recorded in 2022.
  • Peak YoY movement for EBIAT: soared 223.32% in 2023, then plummeted 104.78% in 2025.
  • A 4-year view of EBIAT shows it stood at $7.0 million in 2022, then tumbled by 63.36% to $2.5 million in 2023, then soared by 219.97% to $8.2 million in 2024, then tumbled by 37.11% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for CLB's EBIAT are $5.1 million (Q4 2025), $14.2 million (Q3 2025), and $10.6 million (Q2 2025).